Specifications TableTableSubject areaCardiology, AtherosclerosisMore specific subject areaAcute coronary syndrome, Poly-unsaturated fatty acids (PUFAs)Type of dataTables, FiguresHow data was acquiredProspective studyData formatRaw data, AnalyzedExperimental factorsVirtual histology intravascular ultrasound images were quantified using echoPlaque 4.0 software (INDEC Systems, Inc.)Experimental featuresCorrelations between VH-IVUS image data and serum PUFA levels in coronary plaques of 61 cardiovascular patientsData source locationFukushima, JapanData accessibilityData is with this article

Value of the data•The data provides information on the effect of PUFAs on the coronary vascular composition of cardiovascular disease patients.•This data is valuable for further clinical examination of PUFAs and experimental vascular models.•The analysis of plaque composition based on the gray-scale IVUS and VH-IVUS data is expected to be useful for assessing how PUFAs or other substances impact coronary vascular composition.•The data may be potentially valuable to other researchers examining the relationship between PUFAs and vascular calcification.

1. Data {#s0005}
=======

The serum levels of eicosapentaenoic acid (EPA), EPA/arachidonic acid (AA), docosahexaenoic acid (DHA), and DHA/AA in acute coronary syndrome (ACS) patients were lower than those in stable coronary disease (SCD) patients ([Table 1](#t0005){ref-type="table"}) ([Fig. 1](#f0005){ref-type="fig"}). In addition, the vessel and plaque areas in ACS patients were larger than those in SCD patients ([Fig. 2](#f0010){ref-type="fig"}); however, the percentage of fibrous, fibro-fatty, necrotic core, and dense calcium regions at sites of minimal luminal area within culprit lesions were comparable between the two patient groups ([Table 2](#t0010){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}), although the percentage of dense calcium regions in plaques tended to be higher in SCD patients than ACS patients ([Table 2](#t0010){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}). Univariate and multiple logistic regression analyses revealed that low DHA, low EPA, low DHA/AA, and low EPA/AA were independent factors for the risk of ACS ([Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}). The percentage of dense calcium regions in plaques positively correlated with EPA/AA ([Table 5](#t0025){ref-type="table"}, [Fig. 5](#f0025){ref-type="fig"}), EPA ([Table 5](#t0025){ref-type="table"}, [Fig. 6](#f0030){ref-type="fig"}), and DHA ([Table 5](#t0025){ref-type="table"}, [Fig. 7](#f0035){ref-type="fig"}), and EPA/AA was also inversely correlated with %plaque burden (ratio of plaque area to vessel area) ([Table 5](#t0025){ref-type="table"}, [Fig. 4](#f0020){ref-type="fig"}).

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Study population {#s0015}
---------------------

This study was approved by the Fukushima Red Cross Hospital Ethics Committee (April 24, 2012), and written informed consent was obtained from all study subjects before enrollment. The study population consisted of 27 ACS patients, which included those with unstable angina (*n*=6) and acute myocardial infarction (AMI, *n*=21) and 34 SCD patients, which included those with stable effort angina pectoris (EAP, *n*=29) and silent ischemia (*n*=5). The diagnostic and exclusion criteria are described elsewhere [@bib1], [@bib2], [@bib3]. The clinical histories of patients are listed in [Table 1](#t0005){ref-type="table"}.

2.2. IVUS image acquisition and analysis {#s0020}
----------------------------------------

Intravascular ultrasound was used to examine culprit lesions. A phased-array, 20-MHz, 3.2-F IVUS catheter (Eagle Eye, Volcano Corp., Rancho Cordova, CA) was placed into the distal coronary artery and pulled back to the aorto-ostial junction using a motorized catheter pull-back system set at 0.5 mm/s (Eagle Eye, Volcano Corp.). The gray-scale IVUS and captured radiofrequency (VH-IVUS) data were analyzed using echoPlaque 4.0 software (INDEC Systems, Inc., City, State). Corresponding images of IVUS examinations were identified at culprit lesions between segments. The gray-scale IVUS and VH-IVUS images were analyzed at sites of minimal luminal area within culprit lesions, as previously described [@bib4]. Gray-scale IVUS analysis was performed according to the American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies [@bib5]. In the conventional gray-scale IVUS analysis, cross-sectional images were quantified for luminal diameter, vessel diameter, intima diameter, luminal area, vessel area and plaque area. Plaque burden was calculated as the ratio of plaque area to vessel area. The remodeling index was calculated as the ratio of vessel area at the site of the measured lesion (sites of minimal luminal area) to the reference vessel area (average of the proximal and distal reference segments). The four VH-IVUS plaque components were color-coded as follows: dark green (fibrous), light green (fibro fatty), red (necrotic core), and white (dense calcium), and are reported as the area or percentage of plaque area. Representative images of lesions from ACS (low EPA/AA ratio; 0.29) and SCD patients (high EPA/AA ratio; 0.82) are shown in [Fig. 1](#f0005){ref-type="fig"}. The intraobserver (*r*=0.98, 0.98 and 0.99) and interobserver (*r*=0.96, 0.97, and 0.98) variability for the measurements were determined to be acceptable ([Table 2](#t0010){ref-type="table"}).

2.3. Laboratory analyses {#s0025}
------------------------

Blood examinations for lipid levels were performed within 2 days prior to PCI. Fasting blood samples were collected and after centrifugation and prompt freezing at −80 °C, serum samples were shipped to SRL, Inc. (Tokyo, Japan) for the measurement of dihomo-gamma-linolenic acid (DGLA), EPA, DHA, and AA levels using a gas chromatography method [@bib6]. Plasma concentrations of hsCRP were quantified using the nephelometry method [@bib7].

2.4. Statistical analysis {#s0030}
-------------------------

Data are presented as the mean±standard deviation. Categorical data are presented as number (*n*) and percentage (%). Categorical and continuous variables were compared between the ACS and SCD groups using the chi-square test and Student׳s unpaired *t*-test, respectively ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). Risk factors of ACS were identified using univariable and multivariable logistic regression analysis. All continuous data were categorized because linearity on the logit-scale could not be achieved with continuous covariables. The factors showing *P*\<0.2 in the univariable test were entered into a multivariable logistic analysis. Significant prognostic factors were selected with a forward selection strategy using the likelihood ratio statistic ([Table 3](#t0015){ref-type="table"}). In addition, multiple logistic analyses were performed using two models to avoid multicollinearity ([Table 4](#t0020){ref-type="table"}). All statistical assessments were two-sided and evaluated at the 0.05 level of significance. Correlations of the EPA, EPA/AA, DHA, and DHA/AA data between the gray-scale and VH-IVUS data are shown in [Table 5](#t0025){ref-type="table"} and [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}. All statistical analyses were performed using SPSS 19.0 for Windows (SPSS Inc., Chicago, IL).

2.5. Limitations {#s0035}
----------------

Two limitations of this data warrant mention. First, the data was obtained at a single center from a relatively small number of patients. Data from a larger number of patients and multiple centers are needed to verify the correlations detected here. Second, the relationship between plaque calcification and PUFAs could not be determined from the data. Further experimental examination will be needed to determine the factors underlying this relationship.
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![Representative VH-IVUS images of lesions with low (0.29; left panel) and high EPA/AA (0.82) ratios (right panel). Both images indicate dark green (fibrous), light green (fibro-fatty), red (necrotic core), and white (dense calcium). The low EPA/AA lesion (left panel) was predominantly fibrous (dark green, 66.89%) and contained few regions of dense calcium (white, 0.37%). In contrast, the high EPA/AA lesion (right panel) contained a high proportion of dense calcium regions (white, 22.76%).](gr1){#f0005}

![Comparisons of gray scale IVUS data between ACS and SCD patients. Lumina area, vessel area and plaque area are presented as area (mm^2^), and plaque burden is presented as percentage (%). N.S: not significant, \**P*\<0.05.](gr2){#f0010}

![Comparisons of the percentages of the four examined component areas within plaque areas determined by VH-IVUS between ACS and SCD patients. N.S., not significant.](gr3){#f0015}

![Correlation between EPA/AA and %Plaque burden. EPA/AA was inversely and significantly correlated with %Plaque burden (*R*=−0.261, *P*=0.048). This figure is based on the data presented in [Table 5](#t0025){ref-type="table"}.](gr4){#f0020}

![Correlation between EPA/AA and %DC. EPA/AA was significantly correlated with %DC (*R*=0.513, *P*\<0.01). This figure is based on the data presented in [Table 5](#t0025){ref-type="table"}.](gr5){#f0025}

![Correlation between EPA and %DC. EPA was significantly correlated with %DC (*R*=0.334, *P*=0.01). This figure is based on the data presented in [Table 5](#t0025){ref-type="table"}.](gr6){#f0030}

![Correlation between DHA/AA and %DC. DHA/AA was significantly correlated with %DC (*R*=0.375, *P*=0.004). This figure is based on the data presented in [Table 5](#t0025){ref-type="table"}.](gr7){#f0035}

###### 

Comparisons of patient characteristics and laboratory data between ACS and SCD patients.

Table 1

  Characteristic             ACS *n*=27 (%)   SCD *n*=34 (%)   *P*
  -------------------------- ---------------- ---------------- ------------
  Age (yrs±SD)               69±14            71±10            0.59511
  Male sex                   20 (74.1)        24 (70.6)        0.763
  ***Clinical histories***                                     
  Diabetes mellitus          18 (66.7)        20 (58.8)        0.5301
  Hypertension               19 (70.4)        24 (70.6)        0.9852
  Dyslipidemia               17 (63.0)        13 (38.2)        0.055
  Smoking                    15 (55.6)        22 (64.7)        0.4674
  Previous PCI               1 (3.7)          12 (35.3)        0.0028\*
  Previous CABG              0 (0)            1 (2.9)          0.3689
  Hemodialysis               1 (3.7)          0 (0)            0.2579
  ***Oral medications***                                       
  CCB                        8 (29.6)         14 (41.2)        0.3509
  ACEI/ARB                   8 (29.6)         17 (50)          0.1081
  Beta-blocker               3 (11.1)         1 (2.9)          0.2004
  Diuretics                  3 (11.1)         2 (5.9)          0.4596
  Antiplatelet drugs         2 (7.4)          20 (58.8)        0.000033\*
  Statin                     5 (18.5)         16 (47.1)        0.0198\*
  DT for DM                  7 (25.9)         12 (35.3)        0.4326
  ***Culprit vessel***                                         
  RCA                        12 (44.4)        11 (32.4)        0.3785
  LAD                        13 (48.1)        17 (50.0)        0.8857
  LCX                        2 (7.4)          6 (17.6)         0.4266
  ***Laboratory data***                                        
  TC (mg/dl)                 203.1±46.6       181.4±30.1       0.0514
  TG (mg/dl)                 150.3±79.7       160.8±103.6      0.75
  HDL-C (mg/dl)              51.6±16.2        50.6±12.3        0.8447
  LDL-C (mg/dl)              131.8±42.3       111.4±27.5       0.1137
  Creatinine (mg/dl)         1.2±0.9          0.9±0.3          0.1488
  Uric acid (mg/dl)          6.0±1.8          5.4±1.3          0.1834
  Na (mEq/l)                 139.0±3.3        141.6±2.0        0.0036\*
  K (mEq/l)                  4.2±0.4          4.3±0.4          0.6478
  CL (mEq/l)                 102.2±3.7        106.0±2.5        0.0003\*
  HbA1c                      6.2±0.8          6.4±1.1          0.5434
  WBC (×10^3^/μl)            9.4±3.2          6.3±2.0          0.0006\*
  Hb (g/dl)                  12.9±3.0         13.6±2.2         0.3977
  Plt (×10^3^/μl)            204±77.4         202.4±43.6       0.9235
  hsCRP (ng/ml)              35410±61327      1958±3818        0.0088\*
  DGLA (μg/ml)               34.5±12.3        37.8±12.2        0.2962
  AA (μg/ml)                 173.4±48.7       174.4±45.5       0.9306
  EPA (μg/ml)                49.5±28.3        92.9±42.1        0.00001\*
  DHA (μg/ml)                121.8±37.7       157.2±38.6       0.0007\*
  EPA/AA                     0.297±0.143      0.568±0.306      0.00005\*
  DHA/AA                     0.732±0.225      0.945±0.290      0.0027\*

Values are the mean±SD or number of patients or (percentage). \*:The difference between ACS and SCD is statistically significant with *P*\<0.05. AA, arachidonic acid; ACEI/ARB, angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker; ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; CCB, Calcium-channel blockers; DGLA, dihomo-gamma-linolenic acid; DHA, docosahexaenoic acid; DT for DM, drug therapy for diabetes mellitus; EPA, eicosapentaenoic acid; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary intervention; Plt, platelet; PUFA, polyunsaturated fatty acids; RCA, right coronary artery; SCD, stable coronary disease; TC, Total cholesterol; TG, Triglyceride; WBC, white blood cell.

###### 

Comparisons of gray scale-IVUS and VH-IVUS data between ACS and SCD patients.

Table 2

                                  ACS (*n*=27)    SCD (*n*=34)    *P*
  ------------------------------- --------------- --------------- ----------
  Gray scale-IVUS data                                            
  Max luminal diameter (mm)       2.078±0.778     1.952±0.281     0.4368
  Min luminal diameter (mm)       1.635±0.195     1.610±0.173     0.6172
  Average luminal diameter (mm)   1.776±0.239     1.762±0.183     0.8131
  Luminal area (mm^2^)            2.531±0.695     2.477±0.526     0.7398
  Max vessel diameter (mm)        4.672±0.907     4.247±0.760     0.0573
  Min vessel diameter (mm)        3.976±1.003     3.595±0.766     0.1063
  Average vessel diameter (mm)    4.340±0.944     3.932±0.749     0.0715
  Vessel area (mm^2^)             15.526±6.140    12.614±4.521    0.0422\*
  Plaque area (mm^2^)             12.995±5.895    10.137±4.457    0.04\*
  Plaque burden (%)               80.685±10.011   77.542±9.589    0.2287
  Max intima thickness (mm)       1.951±0.625     1.619±0.482     0.026\*
  Min intima thickness (mm)       0.595±0.355     0.510±0.379     0.3914
  Average intima thickness (mm)   1.233±0.425     1.078±0.381     0.15
  Remodeling index                1.040±0.425     0.842±0.277     0.0533
  VH-IVUS data                                                    
  Fibrous area (mm^2^)            5.822±3.266     4.217±2.047     0.035\*
  Fibrous area (%)                58.743±10.429   57.004±16.610   0.6443
  Fibrous fatty area (mm^2^)      2.529±2.539     1.843±2.239     0.2791
  Fibrous fatty area (%)          21.271±15.085   20.352±12.647   0.8015
  Necrotic core area (mm^2^)      1.421±1.149     1.064±0.720     0.1749
  Necrotic core area (%)          15.213±9.152    14.724±7.557    0.8246
  Dense calcium area (mm^2^)      0.511±0.681     0.449±0.632     0.7237
  Dense calcium area (%)          4.765±4.504     7.921±14.289    0.284

Data is shown as mean±SD. \*:The difference between ACS and SCD is statistically significant with *P*\<0.05. IVUS, intravascular ultrasound; Max, maximum; Min, minimum; VH-IVUS, virtual histology-intravascular ultrasound; Remodeling index, calculated as the ratio of vessel area at the measured lesion (minimum lumen area site) to the reference vessel area (average of the proximal and distal reference segments).

###### 

Univariate logistic regression analysis for acute coronary syndrome.

Table 3

  Variable               OR      Single variable 95% CI   *P*
  ---------------------- ------- ------------------------ -----------
  Male                   1.19    0.383--3.699             0.763
  Age\>75 years:median   0.825   0.300--2.270             0.71
  LDL-C:median           1.68    0.405--6.962             0.474
  hsCRP≥1350:median      6.984   2.193--22.247            0.001\*
  AA≥167.5:median        0.825   0.300--2.270             0.71
  DHA\<137.3:median      6.857   2.207--21.304            0.001\*
  EPA\<60.6:median       14.3    4.083--50.078            \<0.001\*
  DHA/AA\<0.79:median    3.231   1.122--9.303             0.030\*
  EPA/AA\<0.37:median    8.4     2.609--27.047            \<0.001\*

OR, odds ratio. \*:The value of OR is statistically significant with *P*\<0.05. AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; hsCRP, high-sensitivity C-reactive protein; LDL-C low-density lipoprotein cholesterol.

###### 

Multiple logistic regression analysis for acute coronary syndrome.

Table 4

                        Model 1                 Model 2                           
  --------------------- ----------------------- --------- ----------------------- ---------
  hsCRP≧1350:median     4.456 (1.161--17.106)   0.029\*   5.48 (1.458--20.595)    0.012\*
  EPA\<60.6:median      8.879 (1.776--44.395)   0.008\*                           
  DHA\<137.3:median     1.521 (0.305--7.596)    0.609                             
  EPA/AA\<0.37:median                                     8.235 (1.436--47.227)   0.018\*
  DHA/AA\<0.79:median                                     0.998 (0.168--5.950)    0.999

\*:The value of OR is statistically significant with *P*\<0.05. AA, arachidonic acid; CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; hsCRP, high-sensitivity C-reactive protein; OR, odds ratio.

###### 

Correlation of EPA, EPA/AA, DHA and DHA/AA to gray-scale data and VH-IVUS data.

Table 5

                                  EPA correlation index   *P*       EPA /AA correlation index   *P*         DHA correlation index   *P*     DHA/AA correlation index   *P*
  ------------------------------- ----------------------- --------- --------------------------- ----------- ----------------------- ------- -------------------------- ---------
  Gray scale-IVUS data                                                                                                                                                 
  Max luminal diameter (mm)       −0.155                  0.247     −0.137                      0.304       −105                    0.435   −0.047                     0.724
  Min luminal diameter (mm)       −0.143                  0.264     −0.045                      0.737       −0.07                   0.603   0.158                      0.237
  Average luminal diameter (mm)   −0.077                  0.567     −0.041                      0.761       0.032                   0.814   0.149                      0.263
  Luminal area (mm^2^)            −0.087                  0.47      −0.057                      0.673       0.009                   0.944   0.141                      0.293
  Max vessel diameter (mm)        −0.296                  0.024\*   −0.321                      0.014\*     −0.233                  0.079   −0.233                     0.078
  Min vessel diameter (mm)        −0.233                  0.078     −0.253                      0.055       −0.217                  0.102   −0.201                     0.129
  Average vessel diameter (mm)    −0.267                  0.043\*   −0.285                      0.030\*     −0.222                  0.093   −0.209                     0.116
  Vessel area (mm^2^)             −0.289                  0.028\*   −0.291                      0.027\*     −0.249                  0.059   −0.213                     0.109
  Plaque area (mm^2^)             −0.286                  0.029\*   −0.293                      0.025\*     −0.258                  0.051   −0.235                     0.076
  Plaque burden (%)               −0.185                  0.163     −0.261                      0.048\*     −0.167                  0.212   −0.253                     0.055
  Max intima thickness (mm)       −0.309                  0.018\*   −0.342                      0.009\*     −0.255                  0.053   −0.28                      0.033\*
  Min intima thickness (mm)       0.161                   0.23      −0.182                      0.175       −0.215                  0.108   −0.233                     0.082
  Average intima thickness (mm)   −0.248                  0.06      −0.283                      0.031\*     −0.2                    0.132   −0.236                     0.074
  Remodeling index                −0.157                  0.248     −0.131                      0.341       −0.163                  0.229   −0.083                     0.541
  VH-IVUS data                                                                                                                                                         
  Fibrous area (mm^2^)            −0.294                  0.025\*   −0.292                      0.026\*     −0.233                  0.078   −0.214                     0.106
  Fibrous area (%)                −0.154                  0.248     −0.264                      0.046\*     0.007                   0.96    −0.155                     0.245
  Fibro fatty area (mm^2^)        −0.241                  0.068     −0.249                      0.06        −0.212                  0.111   −0.179                     0.179
  Fibro fatty area (%)            −0.176                  0.186     −0.229                      0.084       −0.134                  0.316   −0.147                     0.271
  Necrotic core area (mm^2^)      −0.073                  0.584     −0.06                       0.656       −0.161                  0.228   −0.122                     0.362
  Necrotic core area (%)          0.107                   0.424     0.141                       0.292       −0.033                  0.805   0.005                      0.97
  Dense calcium area (mm^2^)      0.121                   0.367     0.125                       0.35        0.036                   0.789   0.026                      0.847
  Dense calcium (%)               0.334                   0.011\*   0.513                       \<0.001\*   0.181                   0.174   0.375                      0.004\*

\*:The difference between ACS and SCD is statistically significant with *P*\<0.05. IVUS, intravascular ultrasound; Max, maximum; Min, minimum.
